$NTRBW News
Last published 4w ago
- 4w agoNTRBNTRBWNutriband Inc. announces exercise of warrants at $6.43 for Gross Proceeds of $1,753,274GlobeNewswireORLANDO, Fla., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB), announced today that it has seen 272,671 NTRBW warrants exercised at a strike price of $6.43 for proceeds to the company of $1,753,274.53.
- 2mo agoNTRBNTRBWNutriband CEO, Gareth Sheridan to Attend the Nasdaq Life Sciences Advisory Board (LaB) Biotech SummitGlobeNewswireORLANDO, Fla., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), today announced that its CEO, Gareth Sheridan will attend the inaugural Nasdaq LaB Biotech Summit on September 16th. The
- 2mo agoNTRBNTRBWNutriband Receives USPTO Notice of Publication of Commercial Brand Name Trademarks for Its Abuse Deterrent Fentanyl PatchGlobeNewswireNutriband has received a Notice of Publication from the United States Patent and Trademark Office (USPTO) for commercial brand name trademarks for its lead product, an abuse deterrent fentanyl transdermal system. Once
- 3mo agoNTRBNTRBWNutriband CEO, Gareth Sheridan to Present at the 2026 Georgia Life Sciences Summit as Part of the CEO SpotlightGlobeNewswireORLANDO, Fla., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), today announced that its CEO and Co-Founder, Gareth Sheridan will present at the 2026 Georgia Life Sciences Summit on Aug
- 6mo agoNTRBNTRBWNutriband Inc to Showcase Expanding AI Wellness Product Portfolio and New June Product Launches at ECRM ConferenceGlobeNewswireNutriband's Active Intelligence subsidiary to Showcase Expanding AI Wellness Product Portfolio and New June Product Launches at ECRM Conference Company to Meet with Buyers from Walmart Inc, Walgreens, Amazon.com, Inc.,
- 6mo agoNTRBNTRBWNutriband CEO, Gareth Sheridan Discusses the US Fentanyl Crisis and Company Update on Latest Episode of the Jack Neel PodcastGlobeNewswireORLANDO, Fla., April 22, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), today announced that its CEO and Co-Founder, Gareth Sheridan has featured on the latest episode of the Jack Neel Podcast to
- 7mo agoNTRBNTRBWNutriband Selects Commercial Brand Name for Its Abuse Deterrent Fentanyl PatchGlobeNewswireNutriband has selected the commercial worldwide brand name for its lead product, an abuse deterrent fentanyl transdermal system, and will submit to the FDA for approval per FDA Guidance. Nutriband partnered with Brand
- 8mo agoNTRBNTRBWNutriband Signs Exclusive Distribution Agreement with Innomedica for AVERSA Fentanyl and all Sports Tape products for Costa RicaGlobeNewswireORLANDO, Fla., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. today announced that it has signed an exclusive distribution agreement with Costa Rica Based Innomedica for AVERSA Fentanyl upon approval and all sports
- 9mo agoNTRBNTRBWNutriband Inc. provides summary of Annual Shareholder Meeting Key Discussion PointsGlobeNewswireORLANDO, Fla., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) has provided an update to shareholders on the key milestones and discussions from this years Annual Shareholders Meeting,
- 10mo agoNTRBNTRBWNutriband CEO Publishes Letter to ShareholdersGlobeNewswireORLANDO, Fla., Dec. 31, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) today announced that CEO Gareth Sheridan has published a letter to shareholders providing insights on achievements and
- 10mo agoINTCNTRBNTRBWNutriband Inc. Signs Agreement to Sell Majority Stake of Subsidiary Pocono Pharmaceutical for $5M USD to EarthVision BioGlobeNewswireEarthvision Bio, is currently developing and commercializing its line of sustainable products developed by Dr. Gordon Moore, the founder of Intel, and Dr. Hans Franke, ex-chairman for Chevron Europe Nutriband Inc.
- 10mo agoNTRBNTRBWNutriband Inc. Signs Letter of Intent with Qvanta Group of Companies to Explore Advanced Technology Solutions for Abuse-Deterrent Pharmaceutical Innovation Strategic ExplorationGlobeNewswireORLANDO, Fla., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) ("Nutriband" or the "Company"), a developer of transdermal pharmaceutical products including abuse-deterrent
- 10mo agoNTRBNTRBWNutriband Differentiates Prescription Fentanyl from Illicit Fentanyl in Response to United States Executive Order Designating Fentanyl as a Weapon of Mass DestructionGlobeNewswirePrescription pharmaceutical transdermal fentanyl is a valuable treatment for management of pain in opioid-tolerant patients, severe enough to require daily, around-the-clock, long-term opioid treatment for which
- 1y agoNTRBNTRBWREPEAT — Nutriband Announces Successful Meeting Completed With United States FDA For Its Abuse Deterrent Fentanyl PatchGlobeNewswireNutriband met with US FDA to obtain feedback on the Chemistry, Manufacturing, and Controls plans for AVERSA™ FENTANYL (abuse deterrent transdermal system) through commercialization. Nutriband received final
- 1y agoNTRBNTRBWNutriband Announces Successful Meeting Completed With United States FDA For Its Abuse Deterrent Fentanyl PatchGlobeNewswireNutriband met with US FDA to obtain feedback on the Chemistry, Manufacturing, and Controls plans for AVERSA™ FENTANYL (abuse deterrent transdermal system) through commercialization. Nutriband received final
- 1y agoNTRBNTRBWNutriband Co-Founder Gareth Sheridan Returns as CEOGlobeNewswireORLANDO, Fla., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) has announced that Company founder, Gareth Sheridan has returned as Company CEO. During the period of August 10 until
- 1y agoNTRBNTRBWNutriband Signs Agreement With Brand Institute to Develop the Commercial Brand Name for Its Abuse Deterrent Fentanyl PatchGlobeNewswireNutriband initiates commercial worldwide brand name development for its lead product, an abuse deterrent transdermal system. Nutriband has partnered with Brand Institute, Inc, the global leader in pharmaceutical and
- 1y agoNTRBNTRBWNutriband Files Provisional Patent Application for Enhanced Transdermal Abuse Deterrent TechnologyGlobeNewswireNutriband files provisional patent application to enhance its AVERSA™ transdermal abuse deterrent technology being developed for patches containing opioids and stimulants with a potential for abuse. Nutriband's
- 1y agoNTRBNTRBWNutriband To Present at the Noble Capital Markets' Emerging Growth Virtual Equity ConferenceGlobeNewswireORLANDO, Fla., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW), today announced that its Chairman Serguei Melnik will present at Noble Capital Markets' Emerging Growth Virtual Equity
- 1y agoNTRBNTRBWNutriband Inc. to Present at the MicroCap Rodeo ConferenceGlobeNewswireORLANDO, Fla., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (The Company) (NASDAQ:NTRB) (NASDAQ:NTRBW), announces it will participate in the MicroCap Rodeo Conference, to be held Thursday, June 25, 2025, in New
- 1y agoNTRBNTRBWNutriband Inc. Quarterly Report Highlights Record Revenue for Q2, 2025 up 50.87% YOY and Strategic Progress Toward NDA Filing for AVERSA FentanylGlobeNewswireORLANDO, Fla., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) reported its financial results for the six months ended July 31, 2025. The company reported a strong cash position at
- 1y agoNTRBNTRBWNutriband Inc. announces exercise of warrants at $6.43 for Gross Proceeds of $5,306,000GlobeNewswireORLANDO, Fla., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of abuse deterrent pharmaceutical products announced today that it has seen warrants
- 1y agoNTRBNTRBWNutriband Inc. to Present on the Emerging Growth Conference on August 20, 2025GlobeNewswireORLANDO, Fla., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB) (the "Company") is pleased to announce that it has been invited to present on the Emerging Growth Conference on August 20, 2025. The next
- 1y agoNTRBNTRBWNutriband CEO Gareth Sheridan Seeks Nomination in Upcoming Irish Presidential ElectionGlobeNewswireSheridan will temporarily step aside as CEO to enter the Irish Presidential Election. Company Chairman and President, Serguei Melnik will take over as interim CEO over the course of the campaign and election
- 1y agoNTRBNTRBWFDA Grants Nutriband Meeting Request for Aversa™ Fentanyl Abuse Deterrent Fentanyl PatchGlobeNewswireFDA grants meeting for AVERSA™ FENTANYL (abuse deterrent transdermal system) to provide feedback on the Chemistry, Manufacturing, and Controls plans for the product through commercialization. Nutriband is
- 1y agoNTRBNTRBWNutriband Confirms Record and Pay date for 25% Preferred Stock Dividend as it Targets Filing for FDA ApprovalGlobeNewswireORLANDO, Fla., July 18, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) ("Nutriband" or the "Company") is today reminding shareholders of the key dates associated with its upcoming 25% Preferred
- 1y agoNTRBNTRBWNutriband Announces 25% Preferred Stock Dividend as it targets filing for FDA approvalGlobeNewswireORLANDO, Fla., July 02, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) ("Nutriband" or the "Company") announced today that its Board of Directors has approved and declared a 25% preferred stock
- 1y agoNTRBNTRBWNutriband Inc. added to the Russell Microcap® Index, Russell Microcap Growth® Index, Russell 3000E® Index and Russell 3000E Growth® IndexGlobeNewswireORLANDO, Fla., July 01, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW), has been added as a member of the Russell Microcap, Russell Microcap Growth, Russell 3000E and Russell 3000E Growth Indexes,
- 1y agoCOLLEBSNTRBNTRBW+2Abuse Deterrent Formulations Market Exploding While Estimated to Reach $39 Million In 2025 and $54 Million By 2030GlobeNewswirePALM BEACH, Fla., June 18, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The market for abuse-deterrent opioids is still developing, but it's estimated that replacing extended-release opioids with
- 1y agoNTRBNTRBWNutriband and Kindeva Complete Commercial Manufacturing Process Scale-up for Aversa™ Fentanyl Abuse Deterrent Fentanyl PatchGlobeNewswireNutriband and Kindeva have completed commercial manufacturing process scale-up for its lead product Aversa™ Fentanyl, an abuse-deterrent fentanyl patch Nutriband is partnering with Kindeva to develop
- 1y agoNTRBNTRBWNutriband Announces U.S. Patent Issued for Its Transdermal Abuse Deterrent TechnologyGlobeNewswirePatent issuance expands United States patent coverage for AVERSA™ transdermal abuse deterrent technology AVERSA™ transdermal abuse deterrent technology is protected by a broad international intellectual
- 1y agoNTRBNTRBWNutriband Inc. to present at the 2025 Noble Capital Markets Virtual Equity ConferenceGlobeNewswireORLANDO, Fla., June 03, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) today announced that CEO, Gareth Sheridan will present at Noble Capital Markets' Emerging Growth Virtual Equity Conference on
- 1y agoNTRBNTRBWNutriband Inc. Quarterly Report Highlights Record Revenue for Q1, 2025 up 63% YOY and Strategic Progress Toward NDA Filing for AVERSA FentanylGlobeNewswireORLANDO, Fla., June 02, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) reported its financial results for the first quarter ended April 30, 2025. Nutriband is continuing to expand its
- 1y agoNTRBNTRBWNutriband CEO Publishes Letter to ShareholdersGlobeNewswireORLANDO, Fla., April 30, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) today announced that CEO Gareth Sheridan has published a letter to shareholders providing insights on achievements and
- 1y agoNTRBNTRBWNutriband Granted Patent in Macao for its AVERSA Abuse Deterrent Transdermal TechnologyGlobeNewswireORLANDO, Fla., April 11, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of prescription transdermal pharmaceutical products, today announced that it has
- 1y agoNTRBNTRBWUPDATE – Nutriband Signs Associate Partnership with Charlotte FCGlobeNewswireORLANDO, Fla., April 04, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (the "Company")(NASDAQ:NTRB)(NASDAQ:NTRBW), a developer of transdermal pharmaceutical products, today announced that it has signed an Associate
- 1y agoNTRBNTRBWNutriband Signs Partnership Agreement with Charlotte FCGlobeNewswireORLANDO, Fla., April 04, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (the "Company")(NASDAQ:NTRB)(NASDAQ:NTRBW), a developer of transdermal pharmaceutical products, today announced that it has signed an Associate
- 1y agoNTRBNTRBWNutriband Receives Certificate of Registration for Trademark covering Pharmaceutical and Product Research and Development.GlobeNewswireORLANDO, Fla., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW), a developer of transdermal pharmaceutical products, today announced that it received the Certificate of Registration from
- 1y agoNTRBNTRBWNutriband and Kindeva Drug Delivery Formalize Exclusive Development Partnership for Aversa™ Fentanyl Abuse Deterrent Fentanyl PatchGlobeNewswireNutriband and Kindeva formalize exclusive product development partnership and long-term commitment based on shared development costs in exchange for milestone payments Nutriband is partnering with Kindeva Drug
- 1y agoNTRBNTRBWNutriband Inc. Announces Olympian Anastasia Nichita to Advisory BoardGlobeNewswireORLANDO, Fla., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (the "Company")(NASDAQ:NTRB)(NASDAQ:NTRBW), a developer of transdermal pharmaceutical products, today announced World and European Wrestling Gold medalist
- 1y agoNTRBNTRBWNutriband Receives Notice Of Allowance For New U.S. Patent Covering Its Transdermal Abuse Deterrent Technology Aversa™GlobeNewswireORLANDO, Fla., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of prescription transdermal pharmaceutical products, today announced that it received a
- 1y agoNTRBNTRBWNutriband Issues Letter to ShareholdersGlobeNewswireORLANDO, Fla., Dec. 31, 2024 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) today announced that CEO Gareth Sheridan has published a letter to shareholders highlighting the company's achievements in
- 1y agoNTRBNTRBWNutriband Extends Chinese Patent to Macao for its AVERSA™ Abuse Deterrent Transdermal TechnologyGlobeNewswireNutriband's abuse-deterrent platform technology is now patented in 46 countries and territories covering major global markets. Nutriband is targeting to file for FDA approval for AVERSA™ Fentanyl in the first
- 1y agoNTRBNTRBWNutriband Inc. Quarterly Report Highlights Record Revenue for Q3 up 50.94% YOY and Strategic Progress Toward NDA Filing for AVERSA Fentanyl in 2025GlobeNewswireORLANDO, Fla., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) today reported its financial results for the third quarter ended October 31, 2024. The Company reported a strong cash
- 1y agoNTRBNTRBWNutriband Inc. to Present at The 2024 Noble Conference in Boca Raton on December 4thGlobeNewswireORLANDO, Fla., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) today announced that it will be presenting at the Noble Conference taking place December 3rd and 4th at the Florida Atlantic
- 1y agoNTRBNTRBWNutriband Receives Hong Kong Patent Notice of Publication for Its Aversa™ Abuse Deterrent Transdermal TechnologyGlobeNewswireORLANDO, Fla., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of prescription transdermal pharmaceutical products, today announced that it has
- 2y agoAMRXLLYNTRBNTRBW+2As Fentanyl Crisis Escalates, Abuse-Deterrent Formulations to Zero in on the Rising Epidemic of Opiate AbuseGlobeNewswirePALM BEACH, Fla., Sept. 24, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Abuse-deterrent transdermal technology can be used to prevent the misuse of drugs with abuse potential, such as fentanyl, by
- 3y agoCMNDCYBNLLYMNMD+2Demand for Abuse Deterrent Formulation Technology Skyrocketing as Opiate Abuse is on the RisePR NewswireFinancialNewsMedia.com News Commentary PALM BEACH, Fla., Sept. 20, 2023 /PRNewswire/ -- The demand for abuse deterrent formulation technology is projected to grow due to growing misuse of drugs among the people. Growing
- 3y agoNTRBNTRBWNutriband Inc. to File for Product Distribution Permit in South America with Ecuador's Health RegisterACCESS NewswireORLANDO, FL / ACCESSWIRE / February 15, 2023 / Nutriband Inc. today announced that its has completed the requirements to file its application with Ecuador's Health Register (Registro Sanitar
- 4y agoNTRBNTRBWNutriband With Kindeva Drug Delivery Demonstrate Enhanced Abuse-Deterrent Characteristics for AVERSA(TM) FentanylACCESS NewswireORLANDO, FL / ACCESSWIRE / October 4, 2022 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) with Kindeva Drug Delivery have demonstrated enhanced abuse deterrence kinetics of the Company's patented lead product, Aversa™ Fentanyl, an abuse-deterrent fentany